Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  RA CAPITAL MANAGEMENT, LLC
 2. Date of Event Requiring Statement (Month/Day/Year)
08/08/2007		 3. Issuer Name and Ticker or Trading Symbol
CURIS INC [CRIS]
(Last)
(First)
(Middle)
111 HUNTINGTON AVENUE, SUITE 610, 		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

BOSTON, MA 02199		 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 7,520,564
I
See Footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants to Purchase Common Stock   (2) 08/08/2012 Common Stock 2,632,198 $ 1.02 I See Footnote (3)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
RA CAPITAL MANAGEMENT, LLC
111 HUNTINGTON AVENUE, SUITE 610
BOSTON, MA 02199		     X    
ALDRICH RICHARD
C/O RA CAPITAL MANAGEMENT, LLC
111 HUNTINGTON AVENUE, SUITE 610
BOSTON, MA 02199		     X    
Kolchinsky Peter
C/O RA CAPITAL MANAGEMENT, LLC
111 HUNTINGTON AVENUE, SUITE 610
BOSTON, MA 02199		     X    
RA Capital Biotech Fund II, L.P.
C/O RA CAPITAL MANAGEMENT, LLC
111 HUNTINGTON AVENUE, SUITE 610
BOSTON, MA 02199		     X    
RA Capital Biotech Fund LP
C/O RA CAPITAL MANAGEMENT, LLC
111 HUNTINGTON AVENUE, SUITE 610
BOSTON, MA 02199		     X    

Signatures

/s/ Peter Kolchinsky Manager of RA Capital Management LLC, 08/14/2007
**Signature of Reporting Person Date
/s/ Richard H. Aldrich 08/14/2007
**Signature of Reporting Person Date
/s/ Peter Kolchinsky 08/14/2007
**Signature of Reporting Person Date
/s/ Peter Kolchinsky 08/14/2007
**Signature of Reporting Person Date
/s/ Peter Kolchinsky 08/14/2007
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) These shares represent 7,388,202 shares held by RA Capital Biotech Fund, L.P. ("Fund I"), and 132,362 shares held by RA Capital Biotech Fund II, L.P. ("Fund II"). RA Capital Management, LLC (the "General Partner") is the general partner of each of Fund I and Fund II, and Richard H. Aldrich and Peter Kolchinsky are the sole managers of RA Capital Management, LLC. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
(2) These warrants are exerciseable for cash, provided, however, that the warrants are not exerciseable to the extent the holder of any such warrant, together with any affiliates, holds or beneficially owns more than 9.99% of the outstanding Common Stock of the issuer, unless such restriction is waived by the holder upon not less than 61 days written notice to the issuer.
(3) These warrants represent the right for RA Capital Biotech Fund, L.P. ("Fund I") to acquire 2,585,871 additional shares of Common Stock and for RA Capital Biotech Fund II, L.P. ("Fund II") to acquire 46,327 additional shares of Common Stock, in each case upon the terms and conditions set forth in such warrant. RA Capital Management, LLC (the "General Partner") is the general partner of each of Fund I and Fund II, and Richard H. Aldrich and Peter Kolchinsky are the sole managers of RA Capital Management, LLC. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.